GENOR BIOPHARMA DL-00002 (67N0) - Total Assets
Based on the latest financial reports, GENOR BIOPHARMA DL-00002 (67N0) holds total assets worth €1.32 Billion EUR (≈ $1.55 Billion USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See GENOR BIOPHARMA DL-00002 (67N0) net assets for net asset value and shareholders' equity analysis.
GENOR BIOPHARMA DL-00002 - Total Assets Trend (2021–2024)
This chart illustrates how GENOR BIOPHARMA DL-00002's total assets have evolved over time, based on quarterly financial data.
GENOR BIOPHARMA DL-00002 - Asset Composition Analysis
Current Asset Composition (December 2024)
GENOR BIOPHARMA DL-00002's total assets of €1.32 Billion consist of 82.8% current assets and 17.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 82.1% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €82.65 Million | 6.4% |
| Goodwill | €17.82 Million | 1.4% |
Asset Composition Trend (2021–2024)
This chart illustrates how GENOR BIOPHARMA DL-00002's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of GENOR BIOPHARMA DL-00002.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GENOR BIOPHARMA DL-00002's current assets represent 82.8% of total assets in 2024, a decrease from 83.4% in 2021.
- Cash Position: Cash and equivalents constituted 82.1% of total assets in 2024, up from 76.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 5.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 6.4% of total assets.
GENOR BIOPHARMA DL-00002 Competitors by Total Assets
Key competitors of GENOR BIOPHARMA DL-00002 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
GENOR BIOPHARMA DL-00002 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.93 | 5.76 | 5.76 |
| Quick Ratio | 4.93 | 5.73 | 5.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €826.55 Million | €902.56 Million | €902.56 Million |
GENOR BIOPHARMA DL-00002 - Advanced Valuation Insights
This section examines the relationship between GENOR BIOPHARMA DL-00002's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.32 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | -10.9% |
| Total Assets | €1.29 Billion |
| Market Capitalization | $132.48 Million USD |
Valuation Analysis
Below Book Valuation: The market values GENOR BIOPHARMA DL-00002's assets below their book value (0.10x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: GENOR BIOPHARMA DL-00002's assets decreased by 10.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for GENOR BIOPHARMA DL-00002 (2021–2024)
The table below shows the annual total assets of GENOR BIOPHARMA DL-00002 from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €1.29 Billion ≈ $1.51 Billion |
-10.86% |
| 2023-12-31 | €1.45 Billion ≈ $1.69 Billion |
-31.59% |
| 2022-12-31 | €2.12 Billion ≈ $2.47 Billion |
-26.12% |
| 2021-12-31 | €2.86 Billion ≈ $3.35 Billion |
-- |
About GENOR BIOPHARMA DL-00002
Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally. The company offers GB491, a differentiated CDK4/6 inhibitor for advanced or metastatic breast cancer; GB261, a novel CD3/CD20 bispecific antibody which is in clinical development f… Read more